In our SpA population, the most frequent drug combination was anti-TNF plus anti-IL12/23 (17/23 combinations) likely selected due to active concomitant IBD indication in 9 patients, which restricted the use of IL17-targeting therapies that have shown highly effective for MSK domains.We obtained comparable efficacy outcomes compared to the previously described cases. The gene discussed is TNF; the disease is inflammatory bowel disease.